Explore

Slice the corpus on any axis.

Filter by firm, year, function, metric or slide category — then see the result as a narrative arc, a treemap of slide types, or a catalog of slides.

clear
51,416 slides across 1229 decks match.
Treemap Arc Catalog
Improvement of performance and efficiency are the most important levers in Service – Far fewer activities planned overall
RolandBerger · 2019 · kpi_dashboard
Improvement of performance and efficiency are the most important levers in Service – Far fewer activities planned overall
59% — Share of companies planning activities
 Fewer activities are planned on the Innovation levers – Optimization of the innovation system/process ranks highly in Innovation
RolandBerger · 2019 · kpi_dashboard
Fewer activities are planned on the Innovation levers – Optimization of the innovation system/process ranks highly in Innovation
59% — Share of companies planning activities
 A success story – In the last ten years, the Operations Efficiency Radar has supported many industry leaders
RolandBerger · 2019 · case_study
A success story – In the last ten years, the Operations Efficiency Radar has supported many industry leaders
 The Operations Efficiency Radar has provided a robust view of the priorities by function ...
RolandBerger · 2019 · key_takeaways
The Operations Efficiency Radar has provided a robust view of the priorities by function ...
1 million — data points
 CLMT: Two Competitively Advantaged & Separable Businesses
Barclays · 2023 · segmentation
CLMT: Two Competitively Advantaged & Separable Businesses
$230-$270MM — Adjusted EBITDA
 The New Calumet: A Transformed Company
Barclays · 2023 · roadmap
The New Calumet: A Transformed Company
 Disconnect Between Market and Intrinsic Value?
Barclays · 2023 · valuation
Disconnect Between Market and Intrinsic Value?
$31 - $56 — Intrinsic Equity ($/Unit)
 Specialties: Proven Execution
Barclays · 2023 · financial_analysis
Specialties: Proven Execution
$337 million — Specialties Material Margin
 SAF – Energy’s Fastest Growing Market?
Barclays · 2023 · market_landscape
SAF – Energy’s Fastest Growing Market?
15 — Renewable Jet Yield
 2023: Final Steps in Value Unlock
Barclays · 2023 · timeline
2023: Final Steps in Value Unlock
$250 million — Adjusted EBITDA
 Reconciliation of Net Income (Loss) to Adjusted EBITDA
Barclays · 2023 · financial_analysis
Reconciliation of Net Income (Loss) to Adjusted EBITDA
$67.7 — Adjusted EBITDA
 Top areas for review in phase 2
Deloitte · 2015 · initiative_list
Top areas for review in phase 2
 At a high level, the medical devices pathway has fewer component processes than the equivalent pathway for innovative pharmaceuticals
Deloitte · 2015 · process_diagram
At a high level, the medical devices pathway has fewer component processes than the equivalent pathway for innovative pharmaceuticals
 Currently, the route to patients for in vitro diagnostics does not differ significantly from that of other medical devices
Deloitte · 2015 · process_diagram
Currently, the route to patients for in vitro diagnostics does not differ significantly from that of other medical devices
 The widespread adoption of a new class of drugs for preventing stroke is limited despite clinical and cost-effective benefits
Deloitte · 2015 · case_study
The widespread adoption of a new class of drugs for preventing stroke is limited despite clinical and cost-effective benefits
65% — adoption rate
 Our research highlighted two key challenges in the regulatory stage for innovative medical devices
Deloitte · 2015 · pain_points
Our research highlighted two key challenges in the regulatory stage for innovative medical devices
 Adoption of soft tissue support and repair in breast reconstruction surgery is limited by exclusion from National Tariff
Deloitte · 2015 · case_study
Adoption of soft tissue support and repair in breast reconstruction surgery is limited by exclusion from National Tariff
 Adoption of cardiac devices with longer battery life is poor because procurement decisions are often made to meet short-term budget constraints
Deloitte · 2015 · case_study
Adoption of cardiac devices with longer battery life is poor because procurement decisions are often made to meet short-term budget constraints
30% — cost saving
 Our research highlighted four key challenges in the local commissioning and adoption stage for the early access to innovative in vitro diagnostics
Deloitte · 2015 · pain_points
Our research highlighted four key challenges in the local commissioning and adoption stage for the early access to innovative in vitro diagnostics
 A non-invasive pre-natal test has had limited adoption due to discussions around the inclusion in the national Tariff for the maternity pathway
Deloitte · 2015 · case_study
A non-invasive pre-natal test has had limited adoption due to discussions around the inclusion in the national Tariff for the maternity pathway
 The use of a calprotectin test on individuals with chronic intestinal symptoms saves money and is recommended by NICE, but tests are not widely used
Deloitte · 2015 · case_study
The use of a calprotectin test on individuals with chronic intestinal symptoms saves money and is recommended by NICE, but tests are not widely used
£200m — NHS savings
 We’ve considered whether the current pathways for digital health and precision medicine are fit for purpose
Deloitte · 2015 · diagnosis
We’ve considered whether the current pathways for digital health and precision medicine are fit for purpose
 The current pathway from development to adoption for digital health is varied
Deloitte · 2015 · process_diagram
The current pathway from development to adoption for digital health is varied
 The digital health pathway is not fit for purpose with a number of significant barriers to widespread adoption
Deloitte · 2015 · problem_statement
The digital health pathway is not fit for purpose with a number of significant barriers to widespread adoption
 Future proofing: Digital health
Deloitte · 2015 · problem_statement
Future proofing: Digital health
 Future proofing: Precision Medicine/Companion Diagnostics
Deloitte · 2015 · process_diagram
Future proofing: Precision Medicine/Companion Diagnostics
 Future proofing: Precision medicine and companion diagnostics
Deloitte · 2015 · pain_points
Future proofing: Precision medicine and companion diagnostics
 Future proofing: Precision medicine and companion diagnostics
Deloitte · 2015 · strategic_options
Future proofing: Precision medicine and companion diagnostics
 Pivoting to a High Quality Growth of Clinical Trials in China
LEK · 2022 · cover
Pivoting to a High Quality Growth of Clinical Trials in China
 Foreword: This report summarizes the key strategic trends of clinical development in China, and can be referenced by pharmaceutical companies to support their drug R&D considerations and strategies
LEK · 2022 · other
Foreword: This report summarizes the key strategic trends of clinical development in China, and can be referenced by pharmaceutical companies to support their drug R&D considerations and strategies
 Executive summary: Future China clinical trials will pivot to high quality growth under four main strategic trends
LEK · 2022 · executive_summary
Executive summary: Future China clinical trials will pivot to high quality growth under four main strategic trends
 Based on the key economic and healthcare indexes comparison of China, U.S., and European Union countries, China has a strong foundation for healthcare market growth
LEK · 2022 · market_landscape
Based on the key economic and healthcare indexes comparison of China, U.S., and European Union countries, China has a strong foundation for healthcare market growth
1.4 — Population
 China has and will continue to own the largest patient pool with better affordability, though facing several challenges such as price pressure, lack of patient awareness and cutting-edge innovation
LEK · 2022 · industry_trends
China has and will continue to own the largest patient pool with better affordability, though facing several challenges such as price pressure, lack of patient awareness and cutting-edge innovation
 China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment
LEK · 2022 · market_landscape
China clinical trial has experienced rapid growth over the past five years, driven by favorable policy, accelerated innovative drug developed, and continuous R&D investment
29% — CAGR
 Favorable policy: Over the past 5 years, Chinese government has initiated a series of policies for healthcare industry, mostly positive for innovative drugs
LEK · 2022 · industry_trends
Favorable policy: Over the past 5 years, Chinese government has initiated a series of policies for healthcare industry, mostly positive for innovative drugs
 Accelerated innovative drug developed: China has witnessed a strong growth of early-phase clinical trials, quickly catching up with global innovation capability
LEK · 2022 · market_landscape
Accelerated innovative drug developed: China has witnessed a strong growth of early-phase clinical trials, quickly catching up with global innovation capability
47% — CAGR
 Continuous R&D investment: Robust pharma R&D expenditure and patent number growth have sustained the underlying growth of China clinical trials in the past
LEK · 2022 · industry_trends
Continuous R&D investment: Robust pharma R&D expenditure and patent number growth have sustained the underlying growth of China clinical trials in the past
14% — R&D expenditure CAGR
 Meanwhile, headwinds facing China clinical development are also significant: COVID-19 uncertainties, funding challenges, homogeneous competition and regulatory pressure
LEK · 2022 · pain_points
Meanwhile, headwinds facing China clinical development are also significant: COVID-19 uncertainties, funding challenges, homogeneous competition and regulatory pressure
 However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth
LEK · 2022 · quote_slide
However, ~60% of respondents still show a positive attitude towards future trial number growth, with confidence that China clinical development is pivoting to a high-quality growth
60% — Percent of respondents
 We anticipate 4 strategic trends of clinical trial development under the transformation from extensive growth to quality growth in China
LEK · 2022 · industry_trends
We anticipate 4 strategic trends of clinical trial development under the transformation from extensive growth to quality growth in China
 Chinese pharma companies have surely made some progresses in innovation during the past few years, among which over 800 companies already have Class 1 innovative projects
LEK · 2022 · market_landscape
Chinese pharma companies have surely made some progresses in innovation during the past few years, among which over 800 companies already have Class 1 innovative projects
823 — Number of companies
 Some innovative assets also managed to obtain FDA special designation through filling unmet needs on serious conditions or significant improvement on effectiveness
LEK · 2022 · market_landscape
Some innovative assets also managed to obtain FDA special designation through filling unmet needs on serious conditions or significant improvement on effectiveness
21 — Number of products
 However, past innovation mainly concentrated around heated targets, leading to the rising concern of homogeneous competition for pharmas in China
LEK · 2022 · problem_statement
However, past innovation mainly concentrated around heated targets, leading to the rising concern of homogeneous competition for pharmas in China
57 — Number of molecules
 Stringent regulations and pharmas' commercial considerations are driving the development of truly innovative and differentiated therapies in China
LEK · 2022 · industry_trends
Stringent regulations and pharmas' commercial considerations are driving the development of truly innovative and differentiated therapies in China
 ~70% of respondents also believe that homogeneous competition will relieve in next 5 years with company focus shifting to innovative, differentiated and China-specific drugs
LEK · 2022 · industry_trends
~70% of respondents also believe that homogeneous competition will relieve in next 5 years with company focus shifting to innovative, differentiated and China-specific drugs
70% — Percent of respondents
 In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C&GT, which are expected to largely diversify the China landscape
LEK · 2022 · industry_trends
In the meantime, to tackle homogeneous competition, companies are focusing on a wide range of new modalities, such as BsAb, ADC and C&GT, which are expected to largely diversify the China landscape
124% — Number of newly started clinical trials
 In addition to new modalities, companies are also considering to tackle through discovering new targets, improving drug features and investing in cutting-edge technology platforms
LEK · 2022 · case_study
In addition to new modalities, companies are also considering to tackle through discovering new targets, improving drug features and investing in cutting-edge technology platforms
 Oncology has become the most heated TA for clinical development in China over the past few years
LEK · 2022 · industry_trends
Oncology has become the most heated TA for clinical development in China over the past few years
48% — Number of clinical trials
Next page →